Compare Stocks: CNXU, KIDS, DCTH, and BWAY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BWAY Brainsway	$13.63 +0.4%	$14.89	$7.14 ▼ $17.40	$545.62M	1.25	74,983 shs	190,929 shs
CNXU Conexeu Sciences	$4.40 -7.4%	$7.35	$4.19 ▼ $18.79	$133.98M	N/A	225,603 shs	158,233 shs
DCTH Delcath Systems	$16.40 +1.8%	$15.19	$8.12 ▼ $17.42	$559M	0.57	375,801 shs	368,616 shs
KIDS OrthoPediatrics	$22.76 +1.8%	$22.35	$14.42 ▼ $26.74	$583.55M	0.99	209,440 shs	112,568 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BWAY Brainsway	-0.29%	-0.44%	-7.94%	-5.70%	+75.44%
CNXU Conexeu Sciences	-4.23%	-5.00%	-46.57%	-54.98%	+474,999,900.00%
DCTH Delcath Systems	0.00%	-2.01%	-6.01%	+31.08%	+39.60%
KIDS OrthoPediatrics	+2.43%	+0.04%	-12.87%	+21.60%	+16.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BWAY Brainsway	$13.63 +0.4%	$14.89	$7.14 ▼ $17.40	$545.62M	1.25	74,983 shs	190,929 shs
CNXU Conexeu Sciences	$4.40 -7.4%	$7.35	$4.19 ▼ $18.79	$133.98M	N/A	225,603 shs	158,233 shs
DCTH Delcath Systems	$16.40 +1.8%	$15.19	$8.12 ▼ $17.42	$559M	0.57	375,801 shs	368,616 shs
KIDS OrthoPediatrics	$22.76 +1.8%	$22.35	$14.42 ▼ $26.74	$583.55M	0.99	209,440 shs	112,568 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BWAY Brainsway	-0.29%	-0.44%	-7.94%	-5.70%	+75.44%
CNXU Conexeu Sciences	-4.23%	-5.00%	-46.57%	-54.98%	+474,999,900.00%
DCTH Delcath Systems	0.00%	-2.01%	-6.01%	+31.08%	+39.60%
KIDS OrthoPediatrics	+2.43%	+0.04%	-12.87%	+21.60%	+16.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BWAY Brainsway	2.71	Moderate Buy	$18.20	33.53% Upside
CNXU Conexeu Sciences	2.00	Hold	$20.00	354.55% Upside
DCTH Delcath Systems	2.86	Moderate Buy	$23.17	41.26% Upside
KIDS OrthoPediatrics	2.73	Moderate Buy	$26.44	16.19% Upside

Current Analyst Ratings Breakdown

Latest CNXU, KIDS, DCTH, and BWAY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	KIDS OrthoPediatrics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$29.00
9/10/2026	BWAY Brainsway	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/8/2026	BWAY Brainsway	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$19.00
9/4/2026	DCTH Delcath Systems	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/31/2026	BWAY Brainsway	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$17.00 ➝ $19.00
8/21/2026	DCTH Delcath Systems	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/20/2026	KIDS OrthoPediatrics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$24.00 ➝ $29.00
8/19/2026	BWAY Brainsway	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/17/2026	CNXU Conexeu Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (E-)
8/13/2026	BWAY Brainsway	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $18.80
8/12/2026	BWAY Brainsway	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $20.00

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BWAY Brainsway	$52.22M	10.50	$0.24 per share	57.96	$1.87 per share	7.29
CNXU Conexeu Sciences	N/A	N/A	N/A	N/A	$0.21 per share	N/A
DCTH Delcath Systems	$85.23M	6.68	$0.05 per share	308.18	$3.15 per share	5.21
KIDS OrthoPediatrics	$236.35M	2.51	$0.17 per share	134.41	$13.82 per share	1.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BWAY Brainsway	$7.57M	$0.44	30.98	23.91	N/A	15.65%	12.74%	8.17%	11/10/2026 (Estimated)
CNXU Conexeu Sciences	-$3.92M	-$0.40	N/A	N/A	N/A	N/A	-200.20%	-177.26%	N/A
DCTH Delcath Systems	$2.70M	$0.01	1,641.64	136.67	N/A	0.56%	0.46%	0.42%	11/3/2026 (Estimated)
KIDS OrthoPediatrics	-$39.65M	-$1.68	N/A	N/A	N/A	-15.72%	-8.10%	-5.54%	10/27/2026 (Estimated)

Latest CNXU, KIDS, DCTH, and BWAY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/14/2026	Q3 2026	CNXU Conexeu Sciences	-$0.10	-$0.29	-$0.19	-$0.29	N/A	N/A
8/12/2026	Q2 2026	BWAY Brainsway	$0.10	$0.14	+$0.04	$0.07	$16.54 million	$17.11 million
8/6/2026	Q2 2026	DCTH Delcath Systems	-$0.0891	$0.07	+$0.1591	$0.07	$26.25 million	$29.13 million
8/4/2026	Q2 2026	KIDS OrthoPediatrics	-$0.3022	-$0.26	+$0.0422	-$0.30	$68.21 million	$70.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BWAY Brainsway	N/A	N/A	N/A	N/A	N/A
CNXU Conexeu Sciences	N/A	N/A	N/A	N/A	N/A
DCTH Delcath Systems	N/A	N/A	N/A	N/A	N/A
KIDS OrthoPediatrics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BWAY Brainsway	N/A	3.59	3.27
CNXU Conexeu Sciences	N/A	5.31	5.31
DCTH Delcath Systems	N/A	9.83	8.95
KIDS OrthoPediatrics	0.28	4.78	2.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BWAY Brainsway	30.11%
CNXU Conexeu Sciences	N/A
DCTH Delcath Systems	61.12%
KIDS OrthoPediatrics	69.05%

Insider Ownership

Company	Insider Ownership
BWAY Brainsway	19.00%
CNXU Conexeu Sciences	N/A
DCTH Delcath Systems	19.36%
KIDS OrthoPediatrics	32.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BWAY Brainsway	129	40.21 million	32.57 million	Not Optionable
CNXU Conexeu Sciences	4	28.21 million	N/A	N/A
DCTH Delcath Systems	156	34.70 million	27.98 million	Optionable
KIDS OrthoPediatrics	602	26.11 million	17.62 million	Optionable

CNXU, KIDS, DCTH, and BWAY Headlines

Recent News About These Companies

OrthoPediatrics Surpasses 1,000 PNP Tibia Nail Implantations

September 22 at 7:05 AM | globenewswire.com

OrthoPediatrics Corp.(NasdaqGM:KIDS) added to S&P Healthcare Equipment Select Industry Index

September 21 at 2:27 AM | marketscreener.comM

OrthoPediatrics Corp. (NASDAQ:KIDS) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 20 at 4:28 AM | marketbeat.com

OrthoPediatrics Corp (KIDS) Stock Down 6.0% -- Now Undervalued? GF Score: 84/100

September 17, 2026 | gurufocus.com

OrthoPediatrics (NASDAQ:KIDS) Trading Down 3.5% - Time to Sell?

September 17, 2026 | marketbeat.com

OrthoPediatrics' (KIDS) Buy Rating Reiterated at BTIG Research

September 17, 2026 | americanbankingnews.com

OrthoPediatrics (NASDAQ:KIDS) Earns Buy Rating from BTIG Research

September 15, 2026 | marketbeat.com

OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Sells $6,352,772.69 in Stock

September 14, 2026 | americanbankingnews.com

Insider Selling: OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Sells $6,352,772.69 in Stock

September 14, 2026 | americanbankingnews.com

Squarepoint Ops LLC Increases Holdings in OrthoPediatrics Corp. $KIDS

September 13, 2026 | marketbeat.com

OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Sells 302,369 Shares

September 12, 2026 | insidertrades.com

How Orthopediatrics Corp. (KIDS) Affects Rotational Strategy Timing

September 11, 2026 | news.stocktradersdaily.comN

Insider Selling: OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Sells 302,369 Shares of Stock

September 11, 2026 | marketbeat.com

OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Sells 302,369 Shares

September 11, 2026 | marketbeat.com

OrthoPediatrics (KIDS) Crosses $70M as Guidance Climbs Higher

September 11, 2026 | finance.yahoo.com

OrthoPediatrics (NASDAQ:KIDS) Director David Pelizzon Sells 302,369 Shares

September 11, 2026 | insidertrades.com

Bank of New York Mellon Corp Buys New Stake in OrthoPediatrics Corp. $KIDS

September 11, 2026 | marketbeat.com

OrthoPediatrics (NASDAQ:KIDS) Director David Pelizzon Sells 302,369 Shares of Stock

September 10, 2026 | marketbeat.com

OrthoPediatrics (NASDAQ:KIDS) Sees Strong Trading Volume - What's Next?

September 10, 2026 | marketbeat.com

Wellington Management Group LLP Has $15.20 Million Position in OrthoPediatrics Corp. $KIDS

September 8, 2026 | marketbeat.com

David Pelizzon Sells 22,500 Shares of OrthoPediatrics (NASDAQ:KIDS) Stock

September 5, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNXU, KIDS, DCTH, and BWAY Company Descriptions

Brainsway NASDAQ:BWAY

$13.63 +0.06 (+0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$13.68 +0.04 (+0.33%)

As of 07:30 PM Eastern

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

Conexeu Sciences NASDAQ:CNXU

$4.40 -0.35 (-7.37%)

Closing price 04:00 PM Eastern

Extended Trading

$4.60 +0.20 (+4.55%)

As of 07:30 PM Eastern

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. --- Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property ("IP") developed over more than a decade at the University of British Columbia (the "University") and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University's right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company's only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix ("ECM") formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the "10 Minute Tissue™" concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration ("FDA") clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada.

Delcath Systems NASDAQ:DCTH

$16.40 +0.29 (+1.80%)

Closing price 04:00 PM Eastern

Extended Trading

$16.40 0.00 (-0.03%)

As of 07:30 PM Eastern

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

OrthoPediatrics NASDAQ:KIDS

$22.76 +0.41 (+1.83%)

Closing price 04:00 PM Eastern

Extended Trading

$22.74 -0.03 (-0.11%)

As of 07:30 PM Eastern

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNXU, KIDS, DCTH, and BWAY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNXU, KIDS, DCTH, and BWAY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNXU, KIDS, DCTH, and BWAY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNXU, KIDS, DCTH, and BWAY Company Descriptions

Brainsway NASDAQ:BWAY

Conexeu Sciences NASDAQ:CNXU

Delcath Systems NASDAQ:DCTH

OrthoPediatrics NASDAQ:KIDS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNXU, KIDS, DCTH, and BWAY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNXU, KIDS, DCTH, and BWAY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNXU, KIDS, DCTH, and BWAY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNXU, KIDS, DCTH, and BWAY Company Descriptions

Brainsway NASDAQ:BWAY

Conexeu Sciences NASDAQ:CNXU

Delcath Systems NASDAQ:DCTH

OrthoPediatrics NASDAQ:KIDS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools